Adjunctive Gamma Transcranial Alternating Current Stimulation (Gamma-tACS) on Negative and Cognitive Symptoms in Schizophrenia

Not Applicable

• Conditions: Health Condition 1: F20- Schizophrenia

• Registration Number: CTRI/2023/05/052804
• Lead Sponsor: Central Institute of Psychiatry

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Diagnosis of Schizophrenia using Diagnostic Criteria for Research (DCR) of International Classification of Disease-10th edition (ICD-10, World Health Organization, 1993).

2. Aged between 18- 60 years, right-handed individuals of either sex, giving informed consent.

3. An illness of duration more than 2 years & on stable dose of antipsychotics.

4. The Positive and Negative Syndrome Scale for Schizophrenia (PANSS) negative symptoms score of more than 15.

5. Scale for Assessment of Negative Symptoms (SANS) score more than 20.

6. Calgary Depression Scale for Schizophrenia (CDSS) score less than 7.

7. Score less than or equal to 25 on screening with Hindi Montreal Cognitive Assessment Test (Hindi MoCA).

Exclusion Criteria

1. Presence of comorbid neurological or other psychiatric disorder(s).

2. Patients with comorbid substance dependence in the last 6 months, except nicotine and caffeine.

3. Subjects who have received ECT in the past one month.

4. Patients with contraindications to MRI like pacemakers, metallic implants etc.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Change in negative symptoms in patients with schizophrenia as assessed by PANSS â?? Negative Symptoms Subscale and SANS. <br/ ><br>2. Change in cognitive symptoms in patients with schizophrenia as assessed by MoCA, SCWT and TMT.Timepoint: 1. Change in negative symptoms in PANSS and SANS measured at baseline, 1 week and 4 weeks after initiation of treatment. <br/ ><br>2. Change in MoCA, SCWT and TMT measured at baseline, 1 week and 4 weeks after initiation of treatment.

Secondary Outcome Measures

Name	Time	Method
1. Change in gamma band spectral power and functional connectivity in patients with schizophrenia. <br/ ><br>2. Change in CGI-I scores from baseline to post-treatment in patients with schizophrenia assessed by CGI-I Scale.Timepoint: 1. Change in gamma band spectral power and functional connectivity in patients with schizophrenia at baseline, after receiving first session and 1 week post-treatment. <br/ ><br>2. Change in CGI-I score assessed at baseline, 1 week and 4 weeks post-treatment.